- |||||||||| Clinical, Journal, HEOR: Gender differences in quality of life among patients with myasthenia gravis in China. (Pubmed Central) - Nov 21, 2020
Thus, to improve the HRQoL of women MG patients, symptomatic treatments might not be enough, their comorbid conditions should be considered as well. Additionally, employment status, MG exacerbations, and an active lifestyle have been found as determining factors of the patients' HRQoL, which suggests future interventions should cope with these factors to improve their quality of life.
- |||||||||| Review, Journal: Therapeutic potential of aryl hydrocarbon receptor in autoimmunity. (Pubmed Central) - Nov 19, 2020
In this review, we summarize the effects of AhR on several innate and adaptive immune cells associated with autoimmunity, and the mechanism on how AhR participates in autoimmune diseases. In addition, we also discuss therapeutic potential and application prospect of AhR in autoimmune diseases, so as to provide valuable information for exploring novel and effective approaches to autoimmune disease treatments.
- |||||||||| solithromycin (CEM-101) / Melinta Therap, Fujifilm Holdings
PK/PD data, Journal: Differentiating the Pharmacodynamics and Toxicology of Macrolide and Ketolide Antibiotics. (Pubmed Central) - Nov 19, 2020
This mini-perspective describes that structurally similar macrolides/ketolides have clearly mechanistically distinct effects. Understanding these effects could help in developing and securing regulatory approval of a new macrolide/ketolide that is active against macrolide-resistant pathogenic bacteria.
- |||||||||| Clinical, Journal: Epilepsy and autoimmune diseases: Comorbidity in a national patient cohort. (Pubmed Central) - Nov 19, 2020
Based on a large, unselected patient cohort we find that epilepsy patients more often are prescribed medications used to treat type 1 diabetes mellitus, hypothyroidism, myasthenia gravis and MS. This was true for both men and women, and in most age-groups.
- |||||||||| Review, Journal: Congenital Myasthenic Syndromes. (Pubmed Central) - Nov 18, 2020
Diagnosis can be difficult. Treatment options vary depending on the specific genetic type.
- |||||||||| Review, Journal: Therapeutic and Diagnostic Challenges in Myasthenia Gravis. (Pubmed Central) - Nov 18, 2020
Specific populations of patients with MG including MuSK MG, thymomatous MG, refractory MG, and pregnant women also require special consideration. This article reviews specific cases and an update on current management."
- |||||||||| tacrolimus / Generic mfg.
Clinical, Journal, Monotherapy: Favorable Effects of Tacrolimus Monotherapy on Myasthenia Gravis Patients. (Pubmed Central) - Nov 18, 2020
AEs occurred in 37.5% of patients and were generally mild and reversible. TAC monotherapy is a promising option to rapidly alleviate all symptoms of MG, especially for ptosis and bulbar symptoms.
- |||||||||| Soliris (eculizumab) / Alexion Pharma, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, Journal: A series of patients with refractory myasthenia gravis. (Pubmed Central) - Nov 14, 2020
TAC monotherapy is a promising option to rapidly alleviate all symptoms of MG, especially for ptosis and bulbar symptoms. The percentage of patients with refractory MG in our series (13%) is similar to those reported in previous studies; these patients were often women and presented early onset, severe forms of onset, and repeated relapses requiring hospital admission during follow-up.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Review, Journal, Checkpoint inhibition: Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review. (Pubmed Central) - Nov 14, 2020
Pembrolizumab was the most common causative agent for neuro-ophthalmic complications (32.1%)...While incidence of neuro-ophthalmic IRAEs is low, clinicians involved in the care of cancer patients must be aware of their presentation to facilitate prompt recognition and management. Collaboration between oncology and neuro-ophthalmology teams is required to effectively manage patients and reduce morbidity and mortality.
- |||||||||| Clinical, Journal: Miller Fisher syndrome with bilateral vocal cord paralysis: a case report. (Pubmed Central) - Nov 14, 2020
The occurrence of acute or subacute descending paralysis with involvement of bulbar muscles and respiratory failure can often divert clinicians to a diagnosis of neuromuscular junction disorders (such as botulism or myasthenia gravis), vascular causes like stroke, or electrolyte and metabolic abnormalities. Early identification of Miller Fisher syndrome with appropriate testing is essential to prompt treatment and prevention of further, potentially fatal, deterioration.
- |||||||||| Journal: Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs. (Pubmed Central) - Nov 14, 2020
Early identification of Miller Fisher syndrome with appropriate testing is essential to prompt treatment and prevention of further, potentially fatal, deterioration. These results show that antibodies can inhibit AChR function rapidly and demonstrate the importance of clustering in exploring pathogenic disease mechanisms of MG Abs.
- |||||||||| Preclinical, Journal, IO Biomarker: Therapeutic Effect of Bifidobacterium Administration on Experimental Autoimmune Myasthenia Gravis in Lewis Rats. (Pubmed Central) - Nov 12, 2020
Moreover, the relative abundance of Akkermansia genus was found increased compared to healthy and probiotic treated EAMG rats. In conclusion, our findings confirms that the administration of vital bifidobacteria at EAMG onset has beneficial effects on disease progression; this study further supports preclinical research in human MG to evaluate probiotic efficacy as supplementary therapy in MG.
- |||||||||| Biomarker, Clinical, Journal: Increased serum IL-36γ levels are associated with disease severity in myasthenia gravis patients. (Pubmed Central) - Nov 12, 2020
We elucidated a pattern with a delayed nadir and subsequent poor recovery, featuring a low-frequency decrement; furthermore, we determined the most likely sequential order of the minimum wave in patients with LEMS, and the indicator was useful for differentiation. The serum levels of IL-36γ in patients with MG were increased and positively correlated with disease severity and may thus have potential as a serological MG marker.
- |||||||||| Clinical, Journal: Role of thymus on prognosis of myasthenia gravis in Turkish population. (Pubmed Central) - Nov 11, 2020
In the present study, evaluation of 93 patients with myasthenia gravis was done retrospectively and it was concluded that thymectomy had a positive effect on prognosis, especially in young patients when performed as early as possible. The most successful results were obtained in cases with thymic hyperplasia.
- |||||||||| [VIRTUAL] Chondroblastic osteosarcoma with heterologous rhabdomyosarcomatous differentiation () - Nov 9, 2020 - Abstract #ECP2020ECP_4946;
It is also important to underscore that chondroblastic osteosarcoma undergoing heterologous differentiation is a different entity than a dedifferentiated chondrosarcoma. In keeping with complex genomic alterations reported in osteosarcomas with absence of common genetic lesions our NGS analysis has not revealed any potentially targetable molecular alterations.
- |||||||||| [VIRTUAL] Chondroblastic osteosarcoma with heterologous rhabdomyosarcomatous differentiation () - Nov 9, 2020 - Abstract #ECP2020ECP_3252;
It is also important to underscore that chondroblastic osteosarcoma undergoing heterologous differentiation is a different entity than a dedifferentiated chondrosarcoma. In keeping with complex genomic alterations reported in osteosarcomas with absence of common genetic lesions our NGS analysis has not revealed any potentially targetable molecular alterations.
- |||||||||| [VIRTUAL] Chondroblastic osteosarcoma with heterologous rhabdomyosarcomatous differentiation () - Nov 9, 2020 - Abstract #ECP2020ECP_1578;
It is also important to underscore that chondroblastic osteosarcoma undergoing heterologous differentiation is a different entity than a dedifferentiated chondrosarcoma. In keeping with complex genomic alterations reported in osteosarcomas with absence of common genetic lesions our NGS analysis has not revealed any potentially targetable molecular alterations.
- |||||||||| Review, Journal: Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis. (Pubmed Central) - Nov 7, 2020
Experience with plasma exchange and emerging phase 2 clinical trial data of FcRn antagonists provide proof of concept for IgG lowering in myasthenia gravis. Here we review the IgG lifecycle and the relevance of IgG lowering to myasthenia gravis treatment and summarize the available data on FcRn targeted therapeutics in clinical trials for myasthenia gravis.
- |||||||||| Journal: Prevalence and risk of thyroid diseases in myasthenia gravis. (Pubmed Central) - Nov 6, 2020
All these indicated a genotype-phenotype relationship in MUSK-related CMS. The current population-based study showed a higher prevalence of pre-existing thyroid diseases and a higher cumulative probability of thyroid diseases during follow-up after MG diagnosis than in the general population.
- |||||||||| Journal: Envenoming by the rattlesnake Crotalus durissus ruruima in the state of roraima, Brazil. (Pubmed Central) - Nov 5, 2020
Patients were treated with anticrotalic serum in 70.3% of the cases and antibotropic + anticrotalic serum in 24.3%. The victims of C. d. ruruima in Roraima showed a local symptomatology similar to Bothrops envenoming, while systemic symptoms and laboratory analysis proved kidney and muscular injuries, similar to envenoming by Crotalus d. terrificus in Brazil.
- |||||||||| Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_4210;
CONCLUSIONS This study demonstrates that the majority of patients with PNH treated with eculizumab were started on a dose in the induction phase that was higher than the label-recommended dose of 600 mg, and the mean dose received during the maintenance phase was higher than the label-recommended dose of 900 mg in approximately half of all patients. Future analyses that investigate budget impact of eculizumab in patients with PNH should account for real-world dosing patterns in order to comprehensively assess costs and benefits.
- |||||||||| Clinical, Journal: Patient-acceptable symptom states in myasthenia gravis. (Pubmed Central) - Nov 1, 2020
We have estimated thresholds for commonly-used myasthenia health scales reflecting patient-acceptable states in myasthenia patients. These thresholds indicate a global state-"being well" -rather than a change in scores -or "being better." Therefore, PASS thresholds can be used as secondary endpoints for myasthenia research.
- |||||||||| Review, Journal: Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics. (Pubmed Central) - Nov 1, 2020
Complement's role in pathophysiology, monitoring of disease activity and therapy has been investigated in MG, multiple sclerosis, NMOSD, spinal muscular atrophy, amyotrophic lateral sclerosis, Parkinson, Alzheimer, Huntington disease, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, stroke, and epilepsy. Given the complexity of complement diagnostics and therapeutics, this state-of-the-art review aims to provide a brief description of the complement system for the neurologist, an overview of novel complement inhibitors and updates of complement studies in a wide range of neurological disorders.
- |||||||||| tacrolimus / Generic mfg.
Journal: Regional Features of MuSK Antibody-Positive Myasthenia Gravis in Northeast China. (Pubmed Central) - Nov 1, 2020
Patients with MuSK-MG in Northeast China have a modestly later onset age and a proportion of patients may have a mild form of the disease with delayed disease progression. We confirmed the existence of a rare ocular MuSK-MG phenotype, a high proportion of coexisting with other autoimmune diseases, and a good response to steroids combined with tacrolimus for our MuSK-MG series.
|
